Vanguard Group’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.99M | Sell |
2,498,649
-259,829
| -9% | -$1.04M | ﹤0.01% | 2902 |
|
|
2025
Q1 | $2.51M | Buy |
2,758,478
+125,229
| +5% | +$114K | ﹤0.01% | 3418 |
|
|
2024
Q4 | $7.29M | Buy |
2,633,249
+8,911
| +0.3% | +$24.7K | ﹤0.01% | 3110 |
|
|
2024
Q3 | $13.7M | Sell |
2,624,338
-4,971
| -0.2% | -$26K | ﹤0.01% | 2795 |
|
|
2024
Q2 | $11.7M | Buy |
2,629,309
+210,289
| +9% | +$938K | ﹤0.01% | 2824 |
|
|
2024
Q1 | $18.5M | Buy |
2,419,020
+33,998
| +1% | +$260K | ﹤0.01% | 2642 |
|
|
2023
Q4 | $10.2M | Buy |
2,385,022
+108,937
| +5% | +$464K | ﹤0.01% | 2934 |
|
|
2023
Q3 | $9.56M | Buy |
2,276,085
+880,175
| +63% | +$3.7M | ﹤0.01% | 2915 |
|
|
2023
Q2 | $7.78M | Buy |
1,395,910
+67,620
| +5% | +$377K | ﹤0.01% | 3089 |
|
|
2023
Q1 | $7.61M | Sell |
1,328,290
-15,332
| -1% | -$87.9K | ﹤0.01% | 3092 |
|
|
2022
Q4 | $1.41M | Buy |
1,343,622
+559
| +0% | +$587 | ﹤0.01% | 3793 |
|
|
2022
Q3 | $3.6M | Sell |
1,343,063
-11,153
| -0.8% | -$29.9K | ﹤0.01% | 3493 |
|
|
2022
Q2 | $6.46M | Buy |
1,354,216
+864,603
| +177% | +$4.12M | ﹤0.01% | 3235 |
|
|
2022
Q1 | $2M | Buy |
489,613
+894
| +0.2% | +$3.66K | ﹤0.01% | 3958 |
|
|
2021
Q4 | $3.33M | Sell |
488,719
-122,466
| -20% | -$835K | ﹤0.01% | 3826 |
|
|
2021
Q3 | $7.08M | Buy |
611,185
+275,899
| +82% | +$3.2M | ﹤0.01% | 3447 |
|
|
2021
Q2 | $5.71M | Sell |
335,286
-5,678
| -2% | -$96.7K | ﹤0.01% | 3526 |
|
|
2021
Q1 | $6.75M | Buy |
340,964
+31,850
| +10% | +$631K | ﹤0.01% | 3371 |
|
|
2020
Q4 | $6.38M | Buy |
309,114
+12,077
| +4% | +$249K | ﹤0.01% | 3235 |
|
|
2020
Q3 | $7.81M | Buy |
+297,037
| New | +$7.81M | ﹤0.01% | 2911 |
|